DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Safety and Efficacy of Eletriptan for the Treatment of Migraine in Subjects Unsuccessfully Treated With Nonsteroidal Anti-inflammatory Drugs

Information source: Pfizer
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Migraine

Intervention: eletriptan (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Pfizer

Official(s) and/or principal investigator(s):
Pfizer CT.gov Call Center, Study Director, Affiliation: Pfizer


To assess the safety and efficacy of eletriptan for the treatment of migraine in subjects who had not been adequately treated with non-steroidal antiinflammatory drugs (NSAIDs)

Clinical Details

Official title: A Multicentre, Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Eletriptan 40 Mg for the Treatment of Migraine (With or Without Aura) in Subjects Unsuccessfully Treated With NSAIDS

Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome:

Headache severity and response post-treatment

Functional response post-treatment

Secondary outcome:

Presence of associated symptoms including, nausea, vomiting, phonophobia, and photophobia at baseline and post-treatment

Migraine recurrence post-treatment

Time loss (from normal activities and from work) post-treatment

Subject preference and acceptability post-treatment

Subject satisfaction post-treatment

Adverse events

Physical examination

Vital signs


Headache severity and response at baseline and post-treatment

Functional impairment severity and response at baseline and post-treatment


Minimum age: 18 Years. Maximum age: 55 Years. Gender(s): Both.


Inclusion Criteria:

- Met International Headache Society diagnostic criteria for migraine with or without


- Expected to suffer one to six acute migraine attacks per month based on past history

- Experienced migraines for at least one year prior to entering study, and historically

have not responded to NSAIDs Exclusion Criteria:

- Frequent migraine or frequent concomitant non-migrainous headache (average of >6

attacks per month)

- Atypical migraines that consistently failed to respond to adequate medical therapy

- Migraine with prolonged aura, familial hemiplegic migraine, basilar migraine,

migrainous infarction, migraine aura without headache, or migraine with acute-onset aura

Locations and Contacts

Pfizer Investigational Site, Gaziantep, Turkey

Pfizer Investigational Site, Istanbul, Turkey

Pfizer Investigational Site, Izmir, Turkey

Pfizer Investigational Site, Samsun, Turkey

Pfizer Investigational Site, Unknown, Ankara, Turkey

Pfizer Investigational Site, Capa, Istanbul, Turkey

Pfizer Investigational Site, Unknown, Manisa, Turkey

Additional Information

To obtain contact information for a study center near you, click here.

Starting date: November 2002
Last updated: April 22, 2011

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017